The DOI matches its Crossref record; 271 of the 271 references it cites were found in a registry or an index.
The role of the brain reward system in depression
Abstract
The goal of this review is to familiarize the reader about the potential involvement of the brain reward system (BRS) in symptoms of Major Depressive Disorder (MDD). The authors introduce a novel approach to study the pathophysiology of MDD that includes pharmacological probing of BRS pathways (e.g. d-amphetamine, hydromorphone) together with an elicited and measurable behavioral component (e.g. pleasant effects, increased energy, altered cognition). To this date, the major focus of MDD pathophysiology studies has been to characterize biological differences between healthy subjects and depressed patients such as alteration in the monoaminergic and endocrine systems. The relative importance of the various biological changes has not been elucidated, that is, linking these with specific behavioral manifestations in MDD have rarely been attempted. One core symptom of MDD is a decreased experience of pleasure or interest in previously enjoyed activities (i.e. anhedonia) such as work or hobbies, and is accompanied by decreased motivation or drive. The BRS consists of the neural pathways involved in eliciting rewarding experiences in animals and humans. The hypothesis is that altered BRS function may be an underlying brain mechanism of the loss of pleasure/interest experienced in MDD, and will be manifested through an altered response to a BRS probe. The authors have examined BRS function in MDD by introducing a pharmacological probe (i.e. d-amphetamine/d-amph). Amphetamine is defined as a probe due to its ability to release dopamine within major components of the BRS (i.e. the mesocorticolimbic dopamine system.) In addition to the objective pharmacological effects (e.g. altered heart rate), BRS probes like d-amph elicit reliable and measurable behavior, that is, the hedonic effects. A review of the neurobiology of MDD, the BRS, the rationale for implicating the BRS in depressive symptoms, and preliminary data, are presented in this article.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These systems play key roles in neurotransmission, brain maturation, cortical organisation and behaviours (including social behaviour and repetitive behaviour) [180,181,182,183,184].”
From Vitamin D and Autism Spectrum Disorder: A Literature Review (2016) · cites this paper as [182]
In the citing paper
“Multiple lines of evidence suggest an involvement of dysregulated neurotransmitter systems (serotonergic, oxytocinergic and dopaminergic systems) in autism.”
From Vitamin D and Autism Spectrum Disorder: A Literature Review (2016) · cites this paper as [182]
Citations
Cites
A neural substrate of prediction and reward
Schultz, W., Dayan, P., & Montague, P. R. (1997) · Science · doi:10.1126/science.275.5306.1593 · Cited by 9,388
The neural basis of drug craving: An incentive-sensitization theory of addiction
Robinson, T. (1993) · Brain Research Reviews · doi:10.1016/0165-0173(93)90013-p · Cited by 7,346
Predictive reward signal of dopamine neurons
Schultz, W. (1998) · Journal of Neurophysiology · doi:10.1152/jn.1998.80.1.1 · Cited by 4,564
What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?
Berridge, K. C., & Robinson, T. E. (1998) · Brain Research Reviews · doi:10.1016/s0165-0173(98)00019-8 · Cited by 4,127
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Olds, J., & Milner, P. (1954) · Journal of Comparative and Physiological Psychology · doi:10.1037/h0058775 · Cited by 3,176
Ongur, D. (2000) · Cerebral Cortex · doi:10.1093/cercor/10.3.206 · Cited by 2,627
DSM-IV: Diagnostic and Statistical Manual of Mental Disorders
Bell, C. C. (1994) · JAMA · doi:10.1001/jama.1994.03520100096046 · Cited by 2,608
Drug abuse: hedonic homeostatic dysregulation
Koob, G. F., & Moal, M. L. (1997) · Science · doi:10.1126/science.278.5335.52 · Cited by 2,535
McNair, D. M. (1992) · Medical Entomology and Zoology · Cited by 2,527
Research works printed but not linked: 7
- 1999, Guidelines for the Diagnosis and Pharmacological Treatment of Depression
- Cardenas, 2000, Dopaminergic activity in depressed smokers, Br. J. Clin. Pharmacol., 425
- Herbrener, 2000, Anhedonia in schizophrenia: Longitudinal Analyses, American Psychiatric Association Conference. Conference Proceeding
- Jasinski, 1989, Human abuse liability assesment by measurement of subjective and physiological effects. Testing for abuse liability of drugs in humans, NIDA Res. Monogr., 93, 73
- Segal, 1996, Biobehavioral effects of psychoactive drugs (Chapter 16). In Neurobehavioural toxicology and addiction, 451
- Tremblay, 2000, Response to d-amphetamine is altered in Major Depressive Disorder (MDD), Clin. Pharmacol. Ther., 67, 130
- Tremblay, 2000, Probing the Brain Reward System in Major Depressive Disorder: Altered response to d-amphetamine
Cited by
Sorted by citations
Items 101–200 of 244
Triple Reuptake Inhibitors: The Next Generation of Antidepressants
Marks, D., Pae, C., & Patkar, A. A. (2008) · Current Neuropharmacology · doi:10.2174/157015908787386078 · Cited by 61
Breuer, M. E., Chan, J. S. W., Oosting, R. S., Groenink, L., Korte, S. M., Campbell, U. C., Schreiber, R., Hanania, T., Snoeren, E. M. S., Waldinger, M. D., et al. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.07.011 · Cited by 57
Zhou, M., Wang, M.-H., Wang, X., Liu, K., Wan, Y., Li, M., Liu, L., & Zhang, C. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-0365-6 · Cited by 58
Mormède, C., Castanon, N., Medina, C. F., Moze, E., Lestage, J., Neveu, P. J., & Dantzer, R. (2002) · NeuroImmunoModulation · doi:10.1159/000071477 · Cited by 54
Dubol, M., Trichard, C., Leroy, C., Sandu, A., Rahim, M., Granger, B., Tzavara, E. T., Karila, L., Martinot, J., & Eric Artiges, A. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.183 · Cited by 51
Song, N., Liu, Z., Gao, Y., Lu, S., Yang, S., & Yuan, C. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02476-x · Cited by 52
Rizvi, S. J., Salomons, T. V., Konarski, J. Z., Downar, J., Giacobbe, P., McIntyre, R. S., & Kennedy, S. H. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.06.050 · Cited by 45
Meinzer, M. C., Pettit, J. W., Leventhal, A. M., & Hill, R. M. (2012) · Journal of Clinical Psychology · doi:10.1002/jclp.21884 · Cited by 52
Can we call behaviours addictive?
Lemon, J. (2002) · Clinical Psychologist · doi:10.1080/13284200310001707411 · Cited by 48
Rea, E., Rummel, J., Schmidt, T. T., Hadar, R., Heinz, A., Mathé, A. A., & Winter, C. (2013) · Brain stimulation · doi:10.1016/j.brs.2013.09.002 · Cited by 52
Methylene blue and its analogues as antidepressant compounds
Delport, A., Harvey, B. H., Petzer, A., & Petzer, J. P. (2017) · Metabolic Brain Disease · doi:10.1007/s11011-017-0081-6 · Cited by 46
Retinoic acid and depressive disorders: Evidence and possible neurobiological mechanisms
Hu, P., van Dam, A., Wang, Y., Lucassen, P. J., & Zhou, J.-N. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.02.013 · Cited by 48
Lai, C. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.12.086 · Cited by 46
Muneoka, K. T., Shirayama, Y., Takigawa, M., & Shioda, S. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9818-2 · Cited by 45
Depressive and manic symptoms are not opposite poles in bipolar disorder
Johnson, S. L., Morriss, R. K., Scott, J. L., Paykel, E. S., Kinderman, P., Kolamunnage‐Dona, R., & Bentall, R. P. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2010.01602.x · Cited by 44
Real-life validation of reduced reward processing in emerging adults with depressive symptoms.
Bakker, J. M., Goossens, L., Lange, I., Michielse, S., Schruers, K. R. J., Lieverse, R., Marcelis, M. C., van Amelsvoort, T., van Os, J., Myin‐Germeys, I., et al. (2017) · Journal of Abnormal Psychology · doi:10.1037/abn0000294 · Cited by 47
Alvino, L., Constantinides, E., & Franco, M. (2018) · International Journal of Marketing Studies · doi:10.5539/ijms.v10n1p90 · Cited by 47
Does prenatal stress affect latent inhibition? It depends on the gender
Bethus, I., Lemaire, V., LHOMME, M., & Goodall, G. (2004) · Behavioural Brain Research · doi:10.1016/j.bbr.2004.09.013 · Cited by 42
Aida, J., Hikichi, H., Matsuyama, Y., Sato, Y., Tsuboya, T., Tabuchi, T., Koyama, S., Subramanian, S. V., Kondo, K., Osaka, K., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-16636-3 · Cited by 42
Brooks, S. J., Katz, E. S., & Stamoulis, C. (2021) · Cerebral Cortex Communications · doi:10.1093/texcom/tgab062 · Cited by 44
A single social defeat induces short-lasting behavioral sensitization to amphetamine
DEJONG, J., Wasilewski, M., VANDERVEGT, B., Buwalda, B., & KOOLHAAS, J. (2004) · Physiology & Behavior · doi:10.1016/j.physbeh.2004.10.002 · Cited by 41
Rice, F. J., Rawal, A., Riglin, L., Lewis, G., Lewis, G., & Dunsmuir, S. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.07.019 · Cited by 40
MacNicol, B. J. (2016) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-016-0771-2 · Cited by 52
Antidepressant-like effects of glucagon-like peptide-2 in mice occur via monoamine pathways
Iwai, T., Hayashi, Y., Narita, S., Kasuya, Y., Jin, K., Tsugane, M., & Oka, J. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.06.020 · Cited by 40
Pearson, R. M., O’Mahen, H., Burns, A., Bennert, K., Shepherd, C., Baxter, H., Chauhan, D., & Evans, J. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.07.033 · Cited by 42
Mlost, J., Wąsik, A., & Starowicz, K. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.02.029 · Cited by 38
Elevated prolactin responses to l-tryptophan infusion in medication-free depressed patients
Porter, R., Gallagher, P., Watson, S., Smith, M. S., & Young, A. H. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1475-1 · Cited by 35
de Haes, J. I. U., Maguire, R. P., Jager, P. L., Paans, A. M. J., & den Boer, J. A. (2006) · Human Brain Mapping · doi:10.1002/hbm.20293 · Cited by 37
Triple Reuptake Inhibitors (“Broad Spectrum” Antidepressants)
Skolnick, P., & Basile, A. S. (2007) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152707780363285 · Cited by 36
Clark, M. S., McDevitt, R. A., Hoplight, B. J., & Neumaier, J. F. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.03.032 · Cited by 34
A population-based study of blood lead levels in relation to depression in the United States
Golub, N. I., Winters, P., & van Wijngaarden, E. (2009) · International Archives of Occupational and Environmental Health · doi:10.1007/s00420-009-0497-3 · Cited by 34
Gołembiowska, K., Kowalska, M., & Bymaster, F. P. (2011) · Synapse · doi:10.1002/syn.21531 · Cited by 30
Cannabis exacerbates depressive symptoms in rat model induced by reserpine
Khadrawy, Y. A., Sawie, H. G., Abdel‐Salam, O. M. E., & Hosny, E. N. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.02.015 · Cited by 28
Unruh, K. E., Bodfish, J. W., & Gotham, K. O. (2018) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-018-3627-5 · Cited by 28
Major Depression Affects Perceptual Filling-In
Zomet, A., Amiaz, R., Grunhaus, L. J., & Uri Polat, A. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.030 · Cited by 28
The use of dopaminergic and stimulant drugs for the treatment of depression.
Howland, R. (2012) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20120112-03 · Cited by 28
Potter, G. G., Blackwell, A. D., McQuoid, D. R., Payne, M. E., Steffens, D. C., Sahakian, B. J., Welsh-Bohmer, K. A., & Krishnan, K. R. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301339 · Cited by 27
Triple Reuptake Inhibitors: A Premise and Promise
Marks, D. M., Pae, C., & Patkar, A. A. (2008) · Psychiatry Investigation · doi:10.4306/pi.2008.5.3.142 · Cited by 26
The neural markers of MRI to differentiate depression and panic disorder
Lai, C. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.04.013 · Cited by 26
Yang, Y., Zhang, K., Zhong, J., Ju, W., Yu, Z., Lei, X., Chen, X., Quan, Y., Xian, J., Chen, Y., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-31056-7 · Cited by 26
A Simple Fluorescent Aptasensing Platform Based on Graphene Oxide for Dopamine Determination
Teniou, A., Rhouati, A., & Catanante, G. (2022) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-022-03802-1 · Cited by 26
Roth‐Deri, I., Friedman, A., Abraham, L., Lax, E., Flaumenhaft, Y., Dikshtein, Y., & Yadid, G. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.06840.x · Cited by 25
Anderson, K. K., Ballok, D. A., Prasad, N., Szechtman, H., & Šakić, B. (2005) · Behavioural Brain Research · doi:10.1016/j.bbr.2005.07.030 · Cited by 25
The H/Rouen mouse model displays depression-like and anxiety-like behaviors
Yacoubi, M. E., Rappeneau, V., Champion, E., Malleret, G., & Vaugeois, J. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.07.048 · Cited by 22
Parise, L. F., Warren, B. L., Parise, E. M., Iñiguez, S. D., & Bolaños‐Guzmán, C. A. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3434-4 · Cited by 23
Byrns, A., Abdessalem, H. B., Cuesta, M., Bruneau, M., Belleville, S., & Frasson, C. (2020) · Journal of Biomedical Science and Engineering · doi:10.4236/jbise.2020.138018 · Cited by 24
Pharmacological Characterization of Toludesvenlafaxine as a Triple Reuptake Inhibitor
Zhu, H., Wang, W., Sha, C., Guo, W., Li, C., Zhao, F., Wang, H., Jiang, W., & Tian, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.741794 · Cited by 23
Topic, B., Huston, J. P., Náměstková, K., Zhu, S., Mohammed, A. H. S., & Schulz, D. (2008) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2008.06.011 · Cited by 22
Prins, J., Westphal, K. G. C., Korte-Bouws, G. A. H., Quinton, M. S., Schreiber, R., Olivier, B., & Korte, S. M. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.10.001 · Cited by 21
Clinical Pharmacology and Therapeutics of Antidepressants
Ciraulo, D. A., Tsirulnik-Barts, L., Shader, R. I., & Greenblatt, D. J. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-792-5_2 · Cited by 20
Li, H., Sung, H. H., & Lau, C. G. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14102253 · Cited by 18
Rondanelli, M., Opizzi, A., Faliva, M. A., Bucci, M., & Perna, S. (2012) · PubMed · doi:10.3275/8165 · Cited by 19
Skolnick, P. (2005) · Humana Press eBooks · doi:10.1007/978-1-59259-852-6_9 · Cited by 20
Udo de Haes, J. I., Kortekaas, R., Van Waarde, A., Maguire, R. P., Pruim, J., & den Boer, J. A. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0193-2 · Cited by 18
Vacca, G., Ahn, S., & Phillips, A. G. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301173 · Cited by 17
Marutani, T., Yahata, N., Ikeda, Y., Ito, T., Yamamoto, M., Matsuura, M., Matsushima, E., Okubo, Y., Suzuki, H., & Matsuda, T. (2011) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2011.02189.x · Cited by 16
Pérez-Caballero, L., Soto‐Montenegro, M. L., Hidalgo‐Figueroa, M., Micó, J. A., Desco, M., & Berrocoso, E. (2018) · Brain stimulation · doi:10.1016/j.brs.2018.06.010 · Cited by 16
Clinical Pharmacology and Therapeuticsof Antidepressants
Ciraulo, D. A., Shader, R. I., & Greenblatt, D. J. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-435-7_2 · Cited by 17
Cryan, J. F., Sánchez, C., Dinan, T. G., & Borsini, F. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373861-5.00007-2 · Cited by 17
Tan, S. L. T., Handasyde, K. A., Rault, J., & Mendl, M. (2019) · Animal Cognition · doi:10.1007/s10071-019-01318-6 · Cited by 14
Weiß, T., Bernard, R., Bernstein, H., Veh, R. W., & Laube, G. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0254-z · Cited by 14
Raby, W. N., Carpenter, K. M., Aharonovich, E., Rubin, E., Bisaga, A. M., LEVIN, F. R., & Nunes, E. V. (2005) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2005.07.008 · Cited by 15
Pearson, R. M., Lightman, S. L., & Evans, J. (2012) · Archives of Women s Mental Health · doi:10.1007/s00737-012-0269-z · Cited by 14
Wilke, S. A., Lavi, K., Byeon, S., Donohue, K. C., & Sohal, V. S. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.11.008 · Cited by 17
Neurodevelopmental liabilities in alcohol dependence: Central serotonin and dopamine dysfunction
Naranjo, C. A., Chu, A. Y., & Tremblay, L. K. (2002) · Neurotoxicity Research · doi:10.1080/10298420290034231 · Cited by 14
Self-citationPrins, J., Kenny, P. J., Doomernik, I., Schreiber, R., Olivier, B., & Korte, S. M. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.07.047 · Cited by 13
Triple reuptake inhibitors as antidepressants
Skolnick, P., & Basile, A. S. (2006) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2006.10.010 · Cited by 13
Lithium treatment impacts nucleus accumbens shape in bipolar disorder
Vecchio, D., Piras, F., Piras, F., Banaj, N., Janiri, D., Simonetti, A., Sani, G., & Spalletta, G. (2020) · NeuroImage Clinical · doi:10.1016/j.nicl.2020.102167 · Cited by 13
Behavioral Testing in Mouse Models of Stroke
Balkaya, M., & Endres, M. (2010) · Neuromethods · doi:10.1007/978-1-60761-750-1_13 · Cited by 13
Kołosowska, K., Gawryluk, A., Wisłowska-Stanek, A., Liguz‐Lecznar, M., Hetmańczyk, K., Ługowska, A., Sobolewska, A., Skórzewska, A., Gryz, M., & Lehner, M. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.04.009 · Cited by 12
Reynaert, M., Marrocco, J., Gatta, E., Mairesse, J., Camp, G. V., Fagioli, F., Maccari, S., Nicoletti, F., & Morley‐Fletcher, S. (2014) · Advances in neurobiology · doi:10.1007/978-1-4939-1372-5_6 · Cited by 12
Mies, G. W., de Water, E., & Scheres, A. (2016) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.1511 · Cited by 15
Pryce, C. R., Rüedi‐Bettschen, D., Dettling, A. C., & Feldon, J. (2005) · Techniques in the behavioral and neural sciences · doi:10.1016/s0921-0709(05)80048-3 · Cited by 11
Shared Mechanisms of Antidepressant and Antiepileptic Treatments: Drugs and Devices
Jobe, P. C. (2004) · Clinical EEG and Neuroscience · doi:10.1177/155005940403500109 · Cited by 11
Taoka, H., Hamamura, T., Endo, S., Miki, M., Lee, Y., Miyata, S., Toma, K., Ishihara, T., Sagara, H., Gomita, Y., et al. (2006) · Life Sciences · doi:10.1016/j.lfs.2006.01.033 · Cited by 11
Zheng, J., Zhou, L., Gong, X., Yang, F., Cheng, J., Ma, R., Wu, C., Xu, Z., Zhu, W., Yang, H., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116564 · Cited by 10
Rondanelli, M., Klersy, C., Iadarola, P., Monteferrario, F., & Opizzi, A. (2009) · International Journal of Obesity · doi:10.1038/ijo.2009.155 · Cited by 10
Effects of Coffee and Caffeine on Mood and Mood Disorders
Casas, M., Qureshi, A., Prat, G., & Ramos‐Quiroga, J. A. (2004) · Nutrition, brain, and behavior./Nutrition, brain and behavior · doi:10.1201/9780203618851.ch5 · Cited by 10
León, L. A., & Cárdenas, F. P. (2008) · Psychology & Neuroscience · doi:10.3922/j.psns.2008.1.013 · Cited by 9
Duarte, F. S., Lach, G., Martins, P. R. C., Romeiro, G. A., & de Lima, T. C. M. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.08.042 · Cited by 9
Narayanaswamy, J. C., Jose, D., Kalmady, S., Venkatasubramanian, G., & Reddy, Y. J. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867413491153 · Cited by 8
Neurochemical and Behavioural Changes in Rat Models of Depression
Skelin, I., Kovačević, T., & Dikšić, M. (2011) · Croatica Chemica Acta · doi:10.5562/cca1817 · Cited by 8
Chen, Y.-H., Kuo, T., Huang, E. Y., Chou, Y., Chiang, Y. H., Hoffer, B. J., & Miller, J. (2018) · Oncotarget · doi:10.18632/oncotarget.24245 · Cited by 7
Low-anxiety rats are more sensitive to amphetamine in comparison to high-anxiety rats
Lehner, M., Taracha, E., Kaniuga, E., Wisłowska-Stanek, A., Gryz, M., Sobolewska, A., Turzyńska, D., Skórzewska, A., & Płaźnik, A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116667708 · Cited by 7
Animal Models of Depression – Where Are We Going?
Slattery, D. A., & Cryan, J. F. (2010) · Modern trends in psychiatry · doi:10.1159/000319511 · Cited by 7
Esumi, S., Kawasaki, Y., Nakamoto, A., Sagara, H., Gomita, Y., Kitamura, Y., & Sendo, T. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.09.079 · Cited by 8
Methyleugenol Has an Antidepressant Effect in a Neuroendocrine Model: In Silico and In Vivo Evidence
Oliveira, M. C. N., Cavalcante, I. L., de Araújo, A. N., dos Santos, A. M. F., de Menezes, R. P. B., Herrera‐Acevedo, C., de Sousa, N. F., Aquino, J. D. S., Barbosa‐Filho, J. M., de Castro, R. D., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16101408 · Cited by 6
[Inclusion of gaming disorder as a behavioral addiction in ICD-11].
Lindenberg, K., & Holtmann, M. (2021) · Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie · doi:10.1024/1422-4917/a000837 · Cited by 17
Kołosowska, K., Lehner, M., Skórzewska, A., Gawryluk, A., Tomczuk, F., Sobolewska, A., Turzyńska, D., Liguz‐Lecznar, M., Bednarska‐Makaruk, M., Maciejak, P., et al. (2022) · Pharmacological Reports · doi:10.1007/s43440-022-00443-3 · Cited by 5
Alvino, L., Lubbe, R. H. J. V. D., & Constantinides, E. (2018) · Global Fashion Management Conference · doi:10.15444/gmc2018.05.03.04 · Cited by 5
Xu, W., Zang, Y., Shen, Q., Shan, Y., Han, B., Zhou, H., & Lai, X. (2019) · Brain Research · doi:10.1016/j.brainres.2019.146377 · Cited by 5
Triple reuptake inhibitors (TRIs): do they promise us a rose garden?
Köse, S., & Çetin, M. (2018) · Psychiatry and Clinical Psychopharmacology · doi:10.1080/24750573.2018.1443386 · Cited by 5
The Role of Various Types of Diets in the Treatments of Depressive Disorders
Lis, A., Maj, P., Świętek, A., & Romuk, E. B. (2025) · Medicina · doi:10.3390/medicina61101737 · Cited by 5
Molecular-biological problems of drug design and mechanism of drug action
Lapa, G. B. (2011) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-011-0626-7 · Cited by 4
O molekularnej patogenezie stresu i depresji
Pels, K. K. (2020) · Kosmos · doi:10.36921/kos.2020_2619 · Cited by 5
Schmidt, B. L., Santos, M. J., Cariaga-Martínez, A. E., Hill, L., Barloese, M. C. J., & Hall, Z. J. (2017) · Cited by 4
Neuropsychologie der Motivation
Gauggel, S. (2004) · Springer eBooks · doi:10.1007/978-3-662-08959-0_5 · Cited by 4
Miklowitz, D. J., & Johnson, S. L. (2017) · Psychopathology · doi:10.1002/9781394258949.ch8 · Cited by 7
Zhou, W., Zuo, Z., Ji, X., Liu, Q., Xiao, F., Fang, S., Guo, P., Luo, Q., & Wang, X. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-07412-z · Cited by 3
On the neurobiological redefinition of psychiatric symptoms: elimination, reduction, or what?
Lemoine, M. (2016) · Synthese · doi:10.1007/s11229-016-1270-2 · Cited by 3
Metadata
- Authors
- Naranjo, C. A., Tremblay, L. K., & Busto, U. E.
- Affiliations
- Sunnybrook Health Science Centre (CA)
- Corresponding author
- Naranjo, Claudio A.
- Venue
- Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2001-05
- Volume
- 25
- Issue
- 4
- Pages
- 781-823
- ISSN
- 0278-5846 (ISSN-L)
- OpenAlex
- W2040295810
- Cited by
- 245
- References
- 271
- Citations by year
- 2025: 7 · 2024: 5 · 2023: 3 · 2022: 6 · 2021: 7 · 2020: 7 · 2019: 9 · 2018: 13 · 2017: 11 · 2016: 10 · 2015: 8 · 2014: 7 · 2013: 13 · 2012: 13
- FWCI
- 0.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Progress in Neuro-Psychopharmacology and Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cognitive Neuroscience › Neural and Behavioral Psychology Studies
- Keywords
- brain reward system, major depressive disorder, anhedonia, dopamine, mesocorticolimbic dopamine system, amphetamine challenge, hydromorphone, motivation, depression pathophysiology
- MeSH terms
- Amphetamine, Central Nervous System Stimulants, Animals, Brain, Brain Chemistry, Depressive Disorder, Humans, Reward
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review